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The review by Adams and Jones1 has highlighted
the relatively shallow dose-response curve in terms
of effects of inhaled corticosteroids in patients
with asthma. However, it is important to be aware
that endpoints such as lung function, symptoms and
reliever use tend to be downstream markers, poorly
reﬂective of effects upon underlying inﬂammatory
biomarkers and airway hyperresponsiveness. In-
deed, a meta-analysis of 25 studies (n ¼ 963 indivi-
duals) demonstrated that high doses (X1000 mg/
day) of inhaled corticosteroids did confer signiﬁ-
cantly superior effects upon airway hyperrespon-
siveness than lower doses (o1000 mg/day),
amounting to approximately 1 doubling dose/
dilution shift.2 In another study, asthmatics starting
with 3200 mg/day of budesonide had greater nor-
malisation in airway hyperresponsiveness and fewer
exacerbations than individuals using 1600 mg/day.3
In a 2-year study, titrating the inhaled corticoster-
oid dose against airway hyperresponsiveness to
methacholine in conjunction with conventional
parameters of asthma control compared to the
latter alone, resulted in signiﬁcant reductions in
exacerbation frequency and less airway remodel-
ing.4
These data all suggest that management strate-
gies based on lung function and symptoms may
result in inadequate attenuation of the asthmaticee front matter & 2006 Published by Elsevier Ltd.
med.2006.09.010inﬂammatory process and the possibility of sub-
optimal long-term sequeluae. While it is imperative
that patients are not exposed to unnecessary high
doses of inhaled corticosteroids, it is equally
important that clinicians do not lose sight of the
fundamental underlying pathophysiological process
driving symptoms and exacerbations in the persis-
tent asthmatic.References
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